Octapharma Group Publishes 2015 Annual Results Reporting Revenue of €1.5 Billion and Operating Income of €351 Million
The Octapharma Group publishes its 2015 annual results reporting revenue of 1.513 billion Euro, representing an increase of 233 million Euro or 18.2% compared with the 2014 figure.
Gross profit in 2015 was 582 million Euro, 140 million Euro higher than in 2014. The reported gross margin improves to 38.5%.
Operating expenses were 231 million Euro, 60 million Euro higher than in 2014, and include the significant investment Octapharma has made to gain access to new technologies for the development of its recombinant product portfolio.
Operating income is reported at 351 million Euro, the highest in the history of Octapharma. Net cash from operating activities is reported at 382 million Euro or 25% of revenue and provides the platform for future investments.
Chairman and Chief Executive of the Octapharma Group, Wolfgang Marguerre, said: “The year 2015 has been another record-breaking year for Octapharma in which we reached sales in excess of 1.5 billion Euro with a pre-tax profit of 363 million Euro. Being profitable means we can better serve patients globally by investing in the things that make a real difference; making our factories bigger, expanding our fleet of plasma centres, developing new products and exploring novel recombinant technologies.”
Trade receivables and inventory both increased, but at a lower rate than the rate at which sales increased, as a result of careful management of these asset positions.
The investment in fixed assets was 115 million Euro in 2015. Adding the investments into research and development, in 2015 the Octapharma Group invested more than 240 million Euro into the future of the company.
The capacity extension and efficiency improvement program, “Program 2019”, which represents a 400 million Euro investment over 5 years, is well on track.
The equity ratio increases to 84% and underlines the commitment of the shareholders to continue investing profits into the development of the company. This strong financial position empowers Octapharma to invest in strengthening the organisation, allowing it to better fulfil its mission of providing lifesaving products to more chronically ill patients around the world.
To download the full Octapharma Group 2015 Annual Report visit the Octapharma Annual Report website: www.annualreport.octapharma.com
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983.
Octapharma employs more than 6,200 people worldwide to support the treatment of patients in 105 countries with products across three therapeutic areas:
• Haematology (coagulation disorders)
• Immunotherapy (immune disorders)
• Critical Care
Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit www.octapharma.com
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FL-MLB22.9.2018 00:15 | pressemeddelelse
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)
NY-BCW/PALLADINO21.9.2018 19:45 | pressemeddelelse
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice
HEIDELBERG-ENGINEERING21.9.2018 18:43 | pressemeddelelse
Heidelberg Engineering Announces the CE-Marking of ANTERION
JEDOX21.9.2018 17:48 | pressemeddelelse
Florian Winterstein Becomes New CEO of Jedox
AVINOR21.9.2018 16:39 | pressemeddelelse
Avinor to Test Autonomous Snowploughs at Oslo Airport This Winter
MA-TAKEDA-PHARMACEUTICAL21.9.2018 15:32 | pressemeddelelse
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum